APOE ε4 carriage associates with improved myocardial performance from adolescence to older age

Topriceanu, Constantin-Cristian; Shah, Mit; Webber, Matthew; Chan, Fiona; Shiwani, Hunain; Richards, Marcus; Schott, Jonathan; Chaturvedi, Nishi; Moon, James C.; Hughes, Alun D.; Hingorani, Aroon D.; O’Regan, Declan P.; Captur, Gabriella

doi:10.1186/s12872-024-03808-z

BMC Cardiovascular Disorders

Table 4 Associations between APOE ε4 genotypes and echocardiographic data in older age by comparing non-APOE ε4 (ε2ε2, ε2ε3, ε2ε3) with APOE ε4 (ε2ε4, ε3ε4 and ε4ε4) genotypes in ALSPAC

From: APOE ε4 carriage associates with improved myocardial performance from adolescence to older age

s		Model 1 (unadjusted)			Model 2 (adjusted for age, sex, and SEP)		Model 3 (Model 2 + BMI)		Model 4 (Model 2 + CVD)		Model 5 (Model 2 + diabetes)		Model 6 (Model 2 + high cholesterol)		Model 7 (Model 2 + HT)
Outcome	APOE ε4 status	n	Exp β (95% CI)	p-value	Exp β (95% CI)	p-value	Exp β (95% CI)	p-value	Exp β (95% CI)	p-value	Exp β (95% CI)	p-value	Exp β (95% CI)	p-value	Exp β (95% CI)	p-value
EF	No APOE ε4	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
EF	APOE ε4 carriers	1327	1.00 (0.99, 1.01)	0.905	1.00 (0.99, 1.01)	0.737	1.00 (0.99, 1.01)	0.891	1.00 (0.99, 1.01)	0.953	1.00 (0.99, 1.01)	0.899	1.00 (0.99, 1.01)	0.890	1.00 (0.98, 1,01)	0.745
E/e’	No APOE ε4	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
E/e’	APOE ε4 carriers	1333	1.01 (0.98, 1.03)	0.531	1.01 (0.98, 1.03)	0.641	1.01 (0.98, 1.03)	0.540	1.01 (0.98, 1.03)	0.566	1.01 (0.98, 1.03)	0.578	1.01 (0.98, 1.03)	0.619	1.01 (0.99, 1.04)	0.354
LVmass	No APOE ε4	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
LVmass	APOE ε4 carriers	1333	0.98 (0.95, 1.01)	0.171	1.01 (0.98, 1.04)	0.501	0.97 (0.94, 1.00)	0.067	0.98 (0.95, 1.01)	0.171	0.98 (0.95, 1.01)	0.173	0.98 (0.94, 1.01)	0.172	0.98 (0.95, 1.02)	0.248
MCF	No APOE ε4	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
MCF	APOE ε4 carriers	1325	1.02 (1.00, 1.05)	0.059	1.01 (0.99, 1.04)	0.270	1.03 (1.00, 1.05)	0.036	1.02 (1.00, 1.05)	0.060	1.02 (0.99, 1.05)	0.064	1.03 (1.00, 1.06)	0.057	1.02 (0.99, 1.05)	0.169
LVPWT_s	No APOE ε4	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
LVPWT_s	APOE ε4 carriers	1335	0.99 (0.98, 1.01)	0.406	1.00 (0.99, 1.02)	0.784	0.99 (0.98, 1.01)	0.268	0.99 (0.98, 1.01)	0.364	0.99 (0.98, 1.01)	0.413	1.00 (0.98, 1.01)	0.627	0.99 (0.98, 1.01)	0.404
LVPWT_d	No APOE ε4	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
LVPWT_d	APOE ε4 carriers	1335	0.98 (0.97, 1.00)	0.064	1.00 (0.98, 1.01)	0.631	0.98 (0.97, 1.00)	0.032	0.98 (0.97, 1.00)	0.059	0.98 (0.97, 1.00)	0.062	0.98 (0.96, 1.00)	0.029	0.99 (0.97, 1.01)	0.211
IVS_s	No APOE ε4	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
IVS_s	APOE ε4 carriers	1340	0.99 (0.98, 1.01)	0.415	1.00 (0.99, 1.02)	0.743	0.99 (0.97, 1.00)	0.242	0.99 (0.98, 1.01)	0.419	0.99 (0.98, 1.01)	0.422	0.99 (0.98, 1.01)	0.469	0.99 (0.97, 1.01)	0.409
IVS_d	No APOE ε4	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
IVS_d	APOE ε4 carriers	1340	0.98 (0.97, 1.00)	0.057	1.00 (0.98, 1.01)	0.605	0.98 (0.96, 1.00)	0.0231	0.98 (0.97, 1.00)	0.063	0.98 (0.97, 1.00)	0.063	0.99 (0.97, 1.00)	0.125	0.98 (0.96, 1.00)	0.085

All reported analyses here consisted of random-effects meta-analyses of coefficients derived from generalized linear models with gamma distribution and log link from both NSHD and SABRE. Significant p-values are highlighted in bold. Abbreviations as in Tables 1 and 2

Back to article page

ISSN: 1471-2261

Contact us

Submission enquiries: bmccardiovasculardisorders@biomedcentral.com
General enquiries: ORSupport@springernature.com